Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock

About Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc. is led by CEO Yuval Cohen, employs 28 people, headquartered in US, publicly traded since 2014.

Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock trades at $4.05 with a market capitalization of $78.33M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.95, reflecting a net loss over the last twelve months, price-to-book of 1.16, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.99 and $20.56, and currently trades 80.3% below its 52-week high.

On profitability, Corbus Pharmaceuticals Holdings, Inc. generates a return on equity (ROE) of -87.05% (negative, reflecting a net loss), return on capital employed of -101.30%.

Corbus Pharmaceuticals Holdings, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Corbus Pharmaceuticals Holdings, Inc. reported revenue of $2.0M rising to $0, a change of -100.0% across 10 years. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-79.0M.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-102.0M.

Borrowings stand at $2.0M, cash from operations was $-64.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged 65.0% over five years, and was -53.4% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Corbus Pharmaceuticals Holdings, Inc. (CRBP) — frequently asked questions